# Evaluate Bioequivalence of Burotam (1/1 g/Vial)

> **NCT05654090** · PHASE4 · UNKNOWN · sponsor: **Yung Shin Pharm. Ind. Co., Ltd.** · enrollment: 14 (estimated)

## Conditions studied

- Infectious Diseases

## Interventions

- **DRUG:** cefoperazone sodium and sulbactam sodium

## Key facts

- **NCT ID:** NCT05654090
- **Lead sponsor:** Yung Shin Pharm. Ind. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-25
- **Primary completion:** 2022-11-18
- **Final completion:** 2023-02-20
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2023-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05654090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05654090, "Evaluate Bioequivalence of Burotam (1/1 g/Vial)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05654090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*